Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Amivantamab-vmjw |
| Synonyms | |
| Therapy Description |
Rybrevant (amivantamab-vmjw) is a bi-specific antibody that targets EGFR and MET, resulting in inhibition of downstream signaling and potentially leading to decreased growth of EGFR and/or MET-expressing tumors (PMID: 27216193, PMID: 32414908). Rybrevant (amivantamab-vmjw) is FDA-approved for use in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy, in combination with carboplatin and pemetrexed as first-line therapy for adult patients with NSCLC harboring EGFR exon 20 insertion mutations and for patients harboring EGFR exon 19 deletion or L858R who progressed on prior EGFR TKI, and in combination with Lazcluze (lazertinib) as first-line therapy in patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or EGFR L858R (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Amivantamab-vmjw | Rybrevant | JNJ-61186372 | EGFR Antibody 60 MET Antibody 31 | Rybrevant (amivantamab-vmjw) is a bi-specific antibody that targets EGFR and MET, resulting in inhibition of downstream signaling and potentially leading to decreased growth of EGFR and/or MET-expressing tumors (PMID: 27216193, PMID: 32414908). Rybrevant (amivantamab-vmjw) is FDA-approved for use in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy, in combination with carboplatin and pemetrexed as first-line therapy for adult patients with NSCLC harboring EGFR exon 20 insertion mutations and for patients harboring EGFR exon 19 deletion or L858R who progressed on prior EGFR TKI, and in combination with Lazcluze (lazertinib) as first-line therapy in patients with locally advanced or metastatic NSCLC harboring EGFR exon 19 deletions or EGFR L858R (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05379595 | Phase Ib/II | Amivantamab-vmjw Amivantamab-vmjw + Fluorouracil + Irinotecan + Leucovorin Amivantamab-vmjw + Fluorouracil + Leucovorin + Oxaliplatin | A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer (OrigAMI-1) | Recruiting | USA | ITA | ESP | DEU | CAN | BEL | 5 |
| NCT05074940 | Phase II | Amivantamab-vmjw | Amivantamab in Adenoid Cystic Carcinoma | Recruiting | USA | 0 |
| NCT05498428 | Phase II | Amivantamab-vmjw Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium | A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2) | Recruiting | USA | ITA | ISR | GBR | FRA | ESP | DEU | BRA | 4 |
| NCT04606381 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 | A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) | Active, not recruiting | USA | GBR | CAN | 1 |
| NCT03767075 | Phase II | Amivantamab-vmjw Futibatinib Atezolizumab | A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB) | Recruiting | SWE | NLD | ITA | GBR | FRA | ESP | DEU | 0 |
| NCT06385080 | Phase Ib/II | Amivantamab-vmjw Amivantamab-vmjw + Pembrolizumab Amivantamab-vmjw + Paclitaxel | A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-4) | Recruiting | USA | GBR | 3 |
| NCT05845671 | Phase Ib/II | Amivantamab-vmjw | Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations | Recruiting | USA | 0 |
| NCT02609776 | Phase I | Amivantamab-vmjw Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium Amivantamab-vmjw + Lazertinib | Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS) | Active, not recruiting | USA | GBR | FRA | ESP | CAN | AUS | 4 |
| NCT06632236 | Phase I | Amivantamab-vmjw | 5G-EMERALD: Amivantamab in Malignant Brain Tumours (5G-EMERALD) | Recruiting | GBR | 0 |
| NCT04077463 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium Amivantamab-vmjw Lazertinib | A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 5 |
| NCT05117931 | Phase II | Amivantamab-vmjw | A Study of Amivantamab in People With Esophagogastric Cancer | Recruiting | USA | 0 |
CKB BOOST